Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda with or without Avastin in recurrent/metastatic nasopharyngeal carcinoma
NCT03813394Phase 2Active, not recruiting
- Sponsor
- National University Hospital
- Start
- May 2019
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in nasopharyngeal carcinoma (NPC), sponsored by National University Hospital. Started May 2019; status: active, not recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03813394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813394.